| 2024/06/12 | 17:20:14 | Announcement for the term expiration of the Company’s Remuneration Committee | |
| SEQ_NO |
5 |
Date of announcement |
2024/06/12 |
Time of announcement |
17:20:14 |
| Subject |
Announcement for the term expiration of the Company's Remuneration Committee |
| Date of events |
2024/06/12
|
To which item it meets |
paragraph 6 |
| Statement |
1.Date of occurrence of the change:2024/06/12
2.Name of the functional committees:Remuneration Committee
3.Name of the previous position holder:
Chi Hang Yang
Chia Ying Ma
Jerome Shen
4.Resume of the previous position holder:
Chi Hang Yang?GChairman, SVT Investment Co. , Ltd
Chia Ying Ma?GProfessor, Department of Accounting , Soochow University
Jerome Shen?GChairman of Taiwania Capital Biotechnology Corporation
5.Name of the new position holder:Not appointed yet
6.Resume of the new position holder:Not appointed yet
7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’,
‘term expired’, ‘death’ or ‘new appointment’):Term expired
8.Reason for the change:Term expired
9.Original term (from __________ to __________):2021/07/16~2024/07/15
10.Effective date of the new member:Not appointed yet
11.Any other matters that need to be specified:
The new Remuneration Committee will be announced upon appointment
by the Board of Directors. |
|
| 2024/06/12 | 15:20:01 | Announcement for the Members of 4th session of Audit Committee | |
| SEQ_NO |
4 |
Date of announcement |
2024/06/12 |
Time of announcement |
15:20:01 |
| Subject |
Announcement for the Members of 4th session of Audit Committee |
| Date of events |
2024/06/12
|
To which item it meets |
paragraph 6 |
| Statement |
1.Date of occurrence of the change:2024/06/12
2.Name of the functional committees:Audit Committee
3.Name of the previous position holder:
Chi Hang Yang
Chia Ying Ma
Jerome Shen
Jien Wei Yeh
4.Resume of the previous position holder:
Chi Hang Yang?GChairman, SVT Investment Co. , Ltd
Chia Ying Ma?GProfessor, Department of Accounting , Soochow University
Jerome Shen?GChairman of Taiwania Capital Biotechnology Corporation
Jien Wei Yeh?GChair Professor, Department of Material Science
Engineering, National Tsing Hua University
5.Name of the new position holder:
Chi Hang Yang
Chia Ying Ma
Jien Wei Yeh
Feng Shyang Yang
6.Resume of the new position holder:
Chi Hang Yang?GChairman, SVT Investment Co. , Ltd
Chia Ying Ma?GProfessor, Department of Accounting , Soochow University
Jien Wei Yeh?GChair Professor, Department of Material Science Engineering,
National Tsing Hua University
Feng Shyang Yang?GSupervisor, Adimmune Corporation
7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’,
‘term expired’, ‘death’ or ‘new appointment’):Term expired
8.Reason for the change:Term expired
9.Original term (from __________ to __________):2021/07/16~2024/07/15
10.Effective date of the new member:2024/06/12
11.Any other matters that need to be specified:None |
|
| 2024/06/12 | 15:13:50 | Medeon approved to release newly elected Directors or representatives from Non-Competition Restrictions at the Annual Shareholders’ Meeting | |
| SEQ_NO |
3 |
Date of announcement |
2024/06/12 |
Time of announcement |
15:13:50 |
| Subject |
Medeon approved to release newly elected Directors or representatives from Non-Competition Restrictions at the Annual Shareholders' Meeting |
| Date of events |
2024/06/12
|
To which item it meets |
paragraph 21 |
| Statement |
1.Date of the shareholders’ meeting resolution:2024/06/12
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
CENTER LABORATORIES INC. ; Director
Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin;
Director
Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu;
Director
Legal Representative of Medeon, Inc., Yue Teh Jang; Director
Chi Hang Yang; Independent Director
Chia Ying Ma; Independent Director
Jien Wei Yeh; Independent Director
3.Items of competitive conduct in which the officer is
permitted to engage:
Invest in or manage other companies with the same or similar scope of
business as Medeon Biodesign, Inc.
4.Period of permission to engage in the competitive conduct:
During the period of serving as director of Medeon Biodesign, Inc.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
Shares represented at the time of voting: 52,090,101 rights
Number of voting rights of shareholders present at the time of voting
Votes in favor 51,633,784 votes?APercentage of the total represented
share present 99.12%
Votes against 166,110 votes?APercentage of the total represented
share present 0.31%
Votes invalid 0 votes?APercentage of the total represented
share present 0.00%
Votes abstained 290,207 votes?APercentage of the total represented
share present 0.55%
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter ‘N/A’ below):
Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin;
Director
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise:
Director, Beijing Shundu Pharmaceutical Research Institute Co., Ltd.
Director, Shanghai Bio Pharmaceuticals Co., Ltd.
Director, Scindy Pharmaceutical (SuZhou), Ltd.
8.Address of the mainland China enterprise:
Beijing Shundu Pharmaceutical Research Institute Co., Ltd.?GRoom 904,
9th Floor, No. 61, West Balizhuang Li, Chaoyang District, Beijing
Shanghai Bao Pharmaceuticals Co., Ltd?GNo. 28 Luoxin Road, Baoshan
District, Shanghai
Scindy Pharmaceutical (Suzhou) Co., Ltd.?GAddress: 6 / F, Block B,
Building 4, No. 108 Yuxin Road, Suzhou Industrial Park, Suzhou,
Jiangsu, P.R.China
9.Operations of the mainland China enterprise:
Beijing Shundu Pharmaceutical Research Institute Co., Ltd.?G
Biotechnology Services
Shanghai Bio Pharmaceuticals Co., Ltd.?G
Development of Recombinant Protein Drugs and Antibody Drugs
Scindy Pharmaceutical (SuZhou), Ltd.?G
Medical Research and Trial Development
10.Impact on the company’s finance and business:N/A
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:None |
|
| 2024/06/12 | 15:05:56 | Announcement of re-election of Directors at the 2024 Annual Shareholders’ Meeting and the change of more than one-third of Directors | |
| SEQ_NO |
2 |
Date of announcement |
2024/06/12 |
Time of announcement |
15:05:56 |
| Subject |
Announcement of re-election of Directors at the 2024 Annual Shareholders' Meeting and the change of more than one-third of Directors |
| Date of events |
2024/06/12
|
To which item it meets |
paragraph 6 |
| Statement |
1.Date of occurrence of the change:2024/06/12
2.Elected or changed position (Please enter institutional
director, institutional supervisor, independent director,
natural-person director or natural-person supervisor):
institutional director, independent director
3.Title and name of the previous position holder:
Director – Legal Representative of Medeon, Inc.
Yue Teh Jang
Director – Legal Representative of CENTER LABORATORIES INC.
Jung Chin Lin
Director – Legal Representative of CENTER LABORATORIES INC.
Chih Hsiung Wu
Director – Hong Jen Chang
Director – Hsin Yuan Fang
Independent Director – Chi Hang Yang
Independent Director – Chia Ying Ma
Independent Director – Jerome Shen
Independent Director – Jien Wei Yeh
4.Resume of the previous position holder:
Legal Representative of Medeon, Inc., Yue Teh Jang?GGM of Medeon
Biodesign, Inc.
Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin?GDirector
of BioGend Therapeutics Co.,Ltd.
Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu?GChairman
of V-CHECK, INC.
Hong Jen Chang?G Chairman and CEO, YFY Biotech Management Company
Hsin Yuan Fang?GVice Superintendent of Department of Surgery, China Medical
University Hospital
Chi Hang Yang?GChairman, SVT Investment Co. , Ltd
Chia Ying Ma?GProfessor, Department of Accounting , Soochow University
Jerome Shen?GChairman of Taiwania Capital Biotechnology Corporation
Jien Wei Yeh?GChair Professor, Department of Material Science Engineering,
National Tsing Hua University
5.Title and name of the new position holder:
Director – Legal Representative of Medeon, Inc., Yue Teh Jang
Director – Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin
Director – Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu
Independent Director – Chi Hang Yang
Independent Director – Chia Ying Ma
Independent Director – Jien Wei Yeh
Independent Director – Feng Shyang Yang
6.Resume of the new position holder:
Legal Representative of Medeon, Inc., Yue Teh Jang?GGM of Medeon Biodesign,
Inc.
Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin?GDirector
of BioGend Therapeutics Co.,Ltd.
Legal Representative of CENTER LABORATORIES INC., Chih Hsiung Wu?GChairman
of V-CHECK, INC.
Chi Hang Yang?GChairman, SVT Investment Co. , Ltd
Chia Ying Ma?GProfessor, Department of Accounting , Soochow University
Jien Wei Yeh?GChair Professor, Department of Material Science Engineering,
National Tsing Hua University
Feng Shyang Yang?GSupervisor, Adimmune Corporation
7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’,
‘term expired’, ‘death’ or ‘new appointment’):term expired
8.Reason for the change: Term expired and re-elected Directors
9.Number of shares held by the new position holder when elected:
Director – Legal Representative of Medeon, Inc. Yue Teh Jang;
10,450,911 shares
Director – Legal Representative of CENTER LABORATORIES INC. Jung Chin Lin;
27,411,028 shares
Director – Legal Representative of CENTER LABORATORIES INC. Chih Hsiung Wu;
27,411,028 shares
Independent Director – Chi Hang Yang; 0 shares
Independent Director – Chia Ying Ma; 0 shares
Independent Director – Jien Wei Yeh; 0 shares
Independent Director – Feng Shyang Yang; 0 shares
10.Original term (from __________ to __________):2021/07/16~2024/07/15
11.Effective date of the new appointment:2024/06/12
12.Turnover rate of directors of the same term:NA
13.Turnover rate of independent directors of the same term:NA
14.Turnover rate of supervisors of the same term:NA
15.Change in one-third or more of directors (Please enter ‘Yes’ or
‘No’):Yes
16.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None |
|
| 2024/06/12 | 14:51:51 | Announcement for the material resolutions at the 2024 Annual Shareholders’ Meeting. | |
| SEQ_NO |
1 |
Date of announcement |
2024/06/12 |
Time of announcement |
14:51:51 |
| Subject |
Announcement for the material resolutions at the 2024 Annual Shareholders’ Meeting. |
| Date of events |
2024/06/12
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2024/06/12
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2023 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:None
4.Important resolutions III.Business report and financial statements:
Ratification of 2023 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:
Completion of the Election for the 6th session of Directors.
6.Important resolutions V.Other matters:
(1) Approval of the proposal for the private placement to issue
additional common shares
(2) Approval of the release of newly elected directors or its
representatives from Non-Competition Restrictions.
7.Any other matters that need to be specified:None |
|
| 2024/06/07 | 16:38:27 | Medeon is invited to attend the investor conference held by MasterLink Securities | |
| SEQ_NO |
1 |
Date of announcement |
2024/06/07 |
Time of announcement |
16:38:27 |
| Subject |
Medeon is invited to attend the investor conference held by MasterLink Securities |
| Date of events |
2024/06/12
|
To which item it meets |
paragraph 12 |
| Statement |
1.Date of institutional investor conference:2024/06/12
2.Time of institutional investor conference:14:30
3.Location of institutional investor conference:
11F., No. 97, Sec. 2, Dunhua S. Rd., Taipei City (Tunnan Tower, 11F.,
Education and Training Room in MasterLink Securities)
4.Outline of institutional investor conference:
The Company is invited to attend the investor conference held by
MasterLink Securities to outline an overview of the Company’s
current operational status and future development plans.
5.Any other matters that need to be specified:None |
|
| 2024/05/24 | 15:40:10 | BOD of Medeon’s major subsidiary Medeologix re-elected Mr. Yue Teh Jang as the Chairman. | |
| SEQ_NO |
6 |
Date of announcement |
2024/05/24 |
Time of announcement |
15:40:10 |
| Subject |
BOD of Medeon’s major subsidiary Medeologix re-elected Mr. Yue Teh Jang as the Chairman. |
| Date of events |
2024/05/24
|
To which item it meets |
paragraph 6 |
| Statement |
1.Date of the board of directors resolution or date of occurrence of the
change:2024/05/24
2.Position (Please enter chairperson or president/general manager):
Chairperson
3.Name of the previous position holder:Yue Teh Jang
4.Resume of the previous position holder:Chairman, Medeologix Corporation
5.Name of the new position holder:Yue Teh Jang
6.Resume of the new position holder:Chairman, Medeologix Corporation
7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’,
‘term expired’ , ‘job relocation’, ‘severance’, ‘retirement’,
‘death’ or ‘new appointment’):Term expired
8.Reason for the change:Term expired and re-elected
9.Effective date of the new appointment:2024/05/24
10.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None |
|
| 2024/05/24 | 15:34:23 | Major Subsidiary Medeologix Announces Lifting of Non-Compete Restrictions on Directors at 2024 Annual Shareholders’ Meeting. | |
| SEQ_NO |
5 |
Date of announcement |
2024/05/24 |
Time of announcement |
15:34:23 |
| Subject |
Major Subsidiary Medeologix Announces Lifting of Non-Compete Restrictions on Directors at 2024 Annual Shareholders' Meeting. |
| Date of events |
2024/05/24
|
To which item it meets |
paragraph 21 |
| Statement |
1.Date of the shareholders’ meeting resolution:2024/05/24
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
Medeon Biodesign, Inc.
Legal Representative of Medeon Biodesign, Inc. Yue Teh Jang; Chairman
Legal Representative of Medeon Biodesign, Inc. Yih-Cheng Shih; Director
Legal Representative of Medeon Biodesign, Inc. Jenny Chen; Director
ANANT VISHWESHWAR HEGDE; Director
3.Items of competitive conduct in which the officer is
permitted to engage:
Invest in or manage other companies with the same or similar scope of
business as Medeologix
4.Period of permission to engage in the competitive conduct:
During the period of serving as director of Medeologix
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
The proposal was resolved as proposed after the chairman inquired of all
attending shareholders.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter ‘N/A’ below):N/A
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise:N/A
8.Address of the mainland China enterprise:N/A
9.Operations of the mainland China enterprise:N/A
10.Impact on the company’s finance and business:N/A
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:None |
|
| 2024/05/24 | 15:26:46 | Announcement of the Election Results for Directors and Supervisor of Major Subsidiary Medeologix at the 2024 Annual Shareholders’ Meeting. | |
| SEQ_NO |
4 |
Date of announcement |
2024/05/24 |
Time of announcement |
15:26:46 |
| Subject |
Announcement of the Election Results for Directors and Supervisor of Major Subsidiary Medeologix at the 2024 Annual Shareholders' Meeting. |
| Date of events |
2024/05/24
|
To which item it meets |
paragraph 6 |
| Statement |
1.Date of occurrence of the change:2024/05/24
2.Elected or changed position (Please enter institutional
director, institutional supervisor, independent director,
natural-person director or natural-person supervisor):
institutional director, natural-person director, natural-person supervisor
3.Title and name of the previous position holder:
(1) Legal Representative of Medeon Biodesign, Inc. Yue Teh Jang; Chairman
(2) Legal Representative of Medeon Biodesign, Inc. Yih-Cheng Shih; Director
(3) Legal Representative of Medeon Biodesign, Inc. Ming Hsiung Wu; Director
(4) Legal Representative of Medeon Biodesign, Inc. Jenny Chen; Director
(5) ANANT VISHWESHWAR HEGDE; Director
(6) Supervisor: Randy Lin
4.Resume of the previous position holder:
(1) Yue Teh Jang; Chairman of Medeologix Corporation
(2) Yih-Cheng Shih; Director of Medeologix Corporation
(3) Ming Hsiung Wu; Director of Medeologix Corporation
(4) Jenny Chen; Director of Medeologix Corporation
(5) ANANT VISHWESHWAR HEGDE; Director of Medeologix Corporation
(6) Supervisor: Randy Lin; Supervisor of Medeologix Corporation
5.Title and name of the new position holder:
(1) Legal Representative of Medeon Biodesign, Inc. Yue Teh Jang; Chairman
(2) Legal Representative of Medeon Biodesign, Inc. Yih-Cheng Shih; Director
(3) Legal Representative of Medeon Biodesign, Inc. Ming Hsiung Wu; Director
(4) Legal Representative of Medeon Biodesign, Inc. Jenny Chen; Director
(5) ANANT VISHWESHWAR HEGDE; Director
(6) Supervisor: Randy Lin
6.Resume of the new position holder:
(1) Yue Teh Jang; Chairman of Medeologix Corporation
(2) Yih-Cheng Shih; Director of Medeologix Corporation
(3) Ming Hsiung Wu; Director of Medeologix Corporation
(4) Jenny Chen; Director of Medeologix Corporation
(5) ANANT VISHWESHWAR HEGDE; Director of Medeologix Corporation
(6) Supervisor: Randy Lin; Supervisor of Medeologix Corporation
7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’,
‘term expired’, ‘death’ or ‘new appointment’):term expired
8.Reason for the change:Term expired re-elected
9.Number of shares held by the new position holder when elected:
(1) Legal Representative of Medeon Biodesign, Inc.
Yue Teh Jang; 52,814,174 shares
(2) Legal Representative of Medeon Biodesign, Inc.
Yih-Cheng Shih; 52,814,174 shares
(3) Legal Representative of Medeon Biodesign, Inc.
Ming Hsiung Wu; 52,814,174 shares
(4) Legal Representative of Medeon Biodesign, Inc.
Jenny Chen; 52,814,174 shares
(5) ANANT VISHWESHWAR HEGDE; 1,785,826 shares
(6) Supervisor: Randy Lin; 0 shares
10.Original term (from __________ to __________):2021/12/24~2024/12/23
11.Effective date of the new appointment:2024/05/24
12.Turnover rate of directors of the same term:NA
13.Turnover rate of independent directors of the same term:NA
14.Turnover rate of supervisors of the same term:NA
15.Change in one-third or more of directors (Please enter ‘Yes’ or
‘No’):No
16.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None |
|
| 2024/05/24 | 15:10:18 | Announcement for the important resolutions at the 2024 Medeologix Annual Shareholders’ Meeting, on behalf of the major subsidiary, Medeologix | |
| SEQ_NO |
2 |
Date of announcement |
2024/05/24 |
Time of announcement |
15:10:18 |
| Subject |
Announcement for the important resolutions at the 2024 Medeologix Annual Shareholders’ Meeting, on behalf of the major subsidiary, Medeologix |
| Date of events |
2024/05/24
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2024/05/24
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2023 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:
Approval of the amendment to the Articles of Incorporation.
4.Important resolutions III.Business report and financial statements:
Ratification of 2023 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:
Election the 3rd session of Directors and Supervisor
6.Important resolutions V.Other matters:
Approval for the release of newly elected directors or its representatives
from Non-Competition Restrictions.
7.Any other matters that need to be specified:None |
|
